Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

TransMedics (TMDX) Shares Outstanding (2018 - 2026)

TransMedics has reported Shares Outstanding over the past 8 years, most recently at $34.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 1.93% year-over-year to $34.3 million; the TTM value through Dec 2025 reached $34.3 million, up 1.93%, while the annual FY2025 figure was $34.3 million, 1.93% up from the prior year.
  • Shares Outstanding for Q4 2025 was $34.3 million at TransMedics, roughly flat from $34.1 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $34.3 million in Q4 2025 and troughed at $27.5 million in Q1 2021.
  • A 5-year average of $31.5 million and a median of $32.6 million in 2023 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: grew 28.74% in 2021 and later increased 0.98% in 2024.
  • Year by year, Shares Outstanding stood at $27.8 million in 2021, then increased by 15.65% to $32.1 million in 2022, then rose by 1.65% to $32.7 million in 2023, then rose by 2.9% to $33.6 million in 2024, then increased by 1.93% to $34.3 million in 2025.
  • Business Quant data shows Shares Outstanding for TMDX at $34.3 million in Q4 2025, $34.1 million in Q3 2025, and $34.0 million in Q2 2025.